<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33741019</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1756-6606</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular brain</Title>
          <ISOAbbreviation>Mol Brain</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neurodegenerative phosphoprotein signaling landscape in models of SCA3.</ArticleTitle>
        <Pagination>
          <StartPage>57</StartPage>
          <MedlinePgn>57</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">57</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13041-020-00723-0</ELocationID>
        <Abstract>
          <AbstractText>Spinocerebellar ataxia type 3 (SCA3) is a rare neurodegenerative disorder resulting from an aberrant expansion of a polyglutamine stretch in the ataxin-3 protein and subsequent neuronal death. The underlying intracellular signaling pathways are currently unknown. We applied the Reverse-phase Protein MicroArray (RPMA) technology to assess the levels of 50 signaling proteins (in phosphorylated and total forms) using three in vitro and in vivo models expressing expanded ataxin-3: (i) human embryonic kidney (HEK293T) cells stably transfected with human ataxin-3 constructs, (ii) mouse embryonic fibroblasts (MEF) from SCA3 transgenic mice, and (iii) whole brains from SCA3 transgenic mice. All three models demonstrated a high degree of similarity sharing a subset of phosphorylated proteins involved in the PI3K/AKT/GSK3/mTOR pathway. Expanded ataxin-3 strongly interfered (by stimulation or suppression) with normal ataxin-3 signaling consistent with the pathogenic role of the polyglutamine expansion. In comparison with normal ataxin-3, expanded ataxin-3 caused a pro-survival stimulation of the ERK pathway along with reduced pro-apoptotic and transcriptional responses.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sowa</LastName>
            <ForeName>Anna S</ForeName>
            <Initials>AS</Initials>
            <Identifier Source="ORCID">0000-0003-0741-7477</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Rare Diseases, University of Tuebingen, 72076, Tuebingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Popova</LastName>
            <ForeName>Taissia G</ForeName>
            <Initials>TG</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Applied Proteomics and Molecular Medicine, College of Science, George Mason University, Manassas, VA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harmuth</LastName>
            <ForeName>Tina</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-4833-8057</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Rare Diseases, University of Tuebingen, 72076, Tuebingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weber</LastName>
            <ForeName>Jonasz J</ForeName>
            <Initials>JJ</Initials>
            <Identifier Source="ORCID">0000-0003-3758-1569</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Rare Diseases, University of Tuebingen, 72076, Tuebingen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Human Genetics, Ruhr-University Bochum, Universitaetsstrasse 150, 44801, Bochum, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pereira Sena</LastName>
            <ForeName>Priscila</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-2061-5470</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Rare Diseases, University of Tuebingen, 72076, Tuebingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schmidt</LastName>
            <ForeName>Jana</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-8807-9515</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Rare Diseases, University of Tuebingen, 72076, Tuebingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hübener-Schmid</LastName>
            <ForeName>Jeannette</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-4973-0923</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Rare Diseases, University of Tuebingen, 72076, Tuebingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schmidt</LastName>
            <ForeName>Thorsten</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-1862-655X</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany. Thorsten.Schmidt@med.uni-tuebingen.de.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Rare Diseases, University of Tuebingen, 72076, Tuebingen, Germany. Thorsten.Schmidt@med.uni-tuebingen.de.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Brain</MedlineTA>
        <NlmUniqueID>101468876</NlmUniqueID>
        <ISSNLinking>1756-6606</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>26700-71-0</RegistryNumber>
          <NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.26</RegistryNumber>
          <NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.19.12</RegistryNumber>
          <NameOfSubstance UI="D000067699">Ataxin-3</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067699" MajorTopicYN="N">Ataxin-3</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017827" MajorTopicYN="N">Machado-Joseph Disease</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040081" MajorTopicYN="N">Protein Array Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">AKT (PKB)</Keyword>
        <Keyword MajorTopicYN="Y">Ataxin-3 (ATXN3)</Keyword>
        <Keyword MajorTopicYN="Y">Machado-Joseph disease (MJD)</Keyword>
        <Keyword MajorTopicYN="Y">Neurodegeneration</Keyword>
        <Keyword MajorTopicYN="Y">Phosphoprotein</Keyword>
        <Keyword MajorTopicYN="Y">RPMA</Keyword>
        <Keyword MajorTopicYN="Y">Spinocerebellar ataxia type 3 (SCA3)</Keyword>
        <Keyword MajorTopicYN="Y">mTOR</Keyword>
        <Keyword MajorTopicYN="Y">pERK</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33741019</ArticleId>
        <ArticleId IdType="pmc">PMC7980345</ArticleId>
        <ArticleId IdType="doi">10.1186/s13041-020-00723-0</ArticleId>
        <ArticleId IdType="pii">10.1186/s13041-020-00723-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Almeida B, Fernandes S, Abreu I, a, &amp; Macedo-Ribeiro, S. Trinucleotide repeats: a structural perspective. Front Neurol. 2013;4:76. doi: 10.3389/fneur.2013.00076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2013.00076</ArticleId>
            <ArticleId IdType="pmc">PMC3687200</ArticleId>
            <ArticleId IdType="pubmed">23801983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almeida B, Abreu IA, Matos CA, Fraga JS, Fernandes S, Macedo MG, Gutiérrez-Gallego R, Pereira PJ, Carvalho AL, Macedo-Ribeiro S. SUMOylation of the brain-predominant Ataxin-3 isoform modulates its interaction with p97. Biochem Biophys Acta. 2015;1852(9):1950–1959. doi: 10.1016/j.bbadis.2015.06.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2015.06.010</ArticleId>
            <ArticleId IdType="pubmed">26073430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderton BH, Betts J, Blackstock WP, Brion JP, Chapman S, Connell J, et al.  Sites of phosphorylation in tau and factors affecting their regulation. Biochem Soc Symp. 2001;67:73–80. doi: 10.1016/j.bbadis.2015.06.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2015.06.010</ArticleId>
            <ArticleId IdType="pubmed">11447841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araujo J, Breuer P, Dieringer S, Krauss S, Dorn S, Zimmermann K, et al.  FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3. Hum Mol Genet. 2011;20(15):2928–2941. doi: 10.1093/hmg/ddr197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddr197</ArticleId>
            <ArticleId IdType="pubmed">21536589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ardito F, Giuliani M, Perrone D, Troiano G, Lo Muzio L. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review) Int J Mol Med. 2017;40(2):271–280. doi: 10.3892/ijmm.2017.3036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2017.3036</ArticleId>
            <ArticleId IdType="pmc">PMC5500920</ArticleId>
            <ArticleId IdType="pubmed">28656226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beauchesne É, Desjardins P, Hazell AS, Butterworth RF. ENOS gene deletion restores blood-brain barrier integrity and attenuates neurodegeneration in the thiamine-deficient mouse brain. J Neurochem. 2009;111(2):452–459. doi: 10.1111/j.1471-4159.2009.06338.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2009.06338.x</ArticleId>
            <ArticleId IdType="pubmed">19686244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertran-Gonzalez J, Chieng BC, Laurent V, Valjent E, Balleine BW. Striatal cholinergic interneurons display activity-related phosphorylation of ribosomal protein S6. PLoS ONE. 2012;7:12. doi: 10.1371/journal.pone.0053195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0053195</ArticleId>
            <ArticleId IdType="pmc">PMC3532298</ArticleId>
            <ArticleId IdType="pubmed">23285266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beurel E, Jope RS. Differential regulation of STAT family members by glycogen synthase kinase-3. J Biol Chem. 2008;283(32):21934–21944. doi: 10.1074/jbc.M802481200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M802481200</ArticleId>
            <ArticleId IdType="pmc">PMC2494932</ArticleId>
            <ArticleId IdType="pubmed">18550525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bichelmeier U, Schmidt T, Hübener J, Boy J, Rüttiger L, Häbig K, Poths S, Bonin M, Knipper M, Schmidt WJ, Wilbertz J, Wolburg H, Laccone F, Riess O. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci. 2007;27(28):7418–7428. doi: 10.1523/JNEUROSCI.4540-06.2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.4540-06.2007</ArticleId>
            <ArticleId IdType="pmc">PMC6672614</ArticleId>
            <ArticleId IdType="pubmed">17626202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014;14(5):359–370. doi: 10.1038/nrc3711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3711</ArticleId>
            <ArticleId IdType="pmc">PMC4049238</ArticleId>
            <ArticleId IdType="pubmed">24739573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boy J, Schmidt T, Wolburg H, Mack A, Nuber S, Böttcher M, et al.  Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Human Mol Genetics. 2009;18(22):4282–4295. doi: 10.1093/hmg/ddp381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddp381</ArticleId>
            <ArticleId IdType="pubmed">19666958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boy J, Schmidt T, Schumann U, Grasshoff U, Unser S, Holzmann C, et al.  A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats. Neurobiol Dis. 2010;37(2):284–293. doi: 10.1016/j.nbd.2009.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2009.08.002</ArticleId>
            <ArticleId IdType="pubmed">19699305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brion JP, Anderton BH, Authelet M, Dayanandan R, Leroy K, Lovestone S, et al. Neurofibrillary tangles and tau phosphorylation. Biochem Soc Symp. 2001;67:81–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11447842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chi H, Chang H-Y, Sang T-K. Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases. Int J Mol Sci. 2018;19(10):3082. doi: 10.3390/ijms19103082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19103082</ArticleId>
            <ArticleId IdType="pmc">PMC6213751</ArticleId>
            <ArticleId IdType="pubmed">30304824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou A-H, Lin A-C, Hong K-Y, Hu S-H, Chen Y-L, Chen J-Y, et al.  p53 activation mediates polyglutamine-expanded ataxin-3 upregulation of Bax expression in cerebellar and pontine nuclei neurons. Neurochem Int. 2011;58(2):145–152. doi: 10.1016/j.neuint.2010.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2010.11.005</ArticleId>
            <ArticleId IdType="pubmed">21092747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drost J, Nonis D, Eich F, Leske O, Damrath E, Brunt ER, et al.  Ataxin-2 modulates the levels of Grb2 and SRC but not ras signaling. J Mol Neurosci. 2013;51(1):68–81. doi: 10.1007/s12031-012-9949-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12031-012-9949-4</ArticleId>
            <ArticleId IdType="pmc">PMC3739869</ArticleId>
            <ArticleId IdType="pubmed">23335000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Einspahr JG, Calvert V, Alberts DS, Curiel-Lewandrowski C, Warneke J, Krouse R, et al.  Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma. Cancer Prev Res. 2012;5(3):403–413. doi: 10.1158/1940-6207.CAPR-11-0427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1940-6207.CAPR-11-0427</ArticleId>
            <ArticleId IdType="pmc">PMC3297971</ArticleId>
            <ArticleId IdType="pubmed">22389437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evert BO, Schelhaas J, Fleischer H, de Vos R, a I., Brunt, E. R., Stenzel, W.,, et al.  Neuronal intranuclear inclusions, dysregulation of cytokine expression and cell death in spinocerebellar ataxia type 3. Clin Neuropathol. 2006;25(6):272–281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17140157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fei E, Jia N, Zhang T, Ma X, Wang H, Liu C, et al.  Phosphorylation of ataxin-3 by glycogen synthase kinase 3β at serine 256 regulates the aggregation of ataxin-3. Biochem Biophys Res Commun. 2007;357(2):487–492. doi: 10.1016/j.bbrc.2007.03.160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2007.03.160</ArticleId>
            <ArticleId IdType="pubmed">17434145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrarelli LK. Conserved signals in neurodegeneration. Sci Signal. 2013;6(281):143. doi: 10.1126/scisignal.2004445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2004445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia D, Shaw RJ. AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance. Mol Cell. 2017;66(6):789–800. doi: 10.1016/j.molcel.2017.05.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2017.05.032</ArticleId>
            <ArticleId IdType="pmc">PMC5553560</ArticleId>
            <ArticleId IdType="pubmed">28622524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hermida MA, Dinesh Kumar J, Leslie NR. GSK3 and its interactions with the PI3K/AKT/mTOR signalling network. Adv Biol Regul. 2017;65:5–15. doi: 10.1016/j.jbior.2017.06.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbior.2017.06.003</ArticleId>
            <ArticleId IdType="pubmed">28712664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010;33(2):67–75. doi: 10.1016/j.tins.2009.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tins.2009.11.003</ArticleId>
            <ArticleId IdType="pmc">PMC2821969</ArticleId>
            <ArticleId IdType="pubmed">19963289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hübener J, Vauti F, Funke C, Wolburg H, Ye Y, Schmidt T, et al.  N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation. Brain. 2011;134(7):1925–1942. doi: 10.1093/brain/awr118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awr118</ArticleId>
            <ArticleId IdType="pubmed">21653538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, et al.  CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q321. Nature Genet. 1994;8(3):221–8. doi: 10.1038/ng1194-221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng1194-221</ArticleId>
            <ArticleId IdType="pubmed">7874163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaytor MD, Byam CE, Tousey SK, Stevens SD, Zoghbi HY, et al.  A cell-based screen for modulators of ataxin-1 phosphorylation. Hum Mol Genet. 2005;14(8):1095–1105. doi: 10.1093/hmg/ddi122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddi122</ArticleId>
            <ArticleId IdType="pubmed">15757972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klotz LO, Sánchez-Ramos C, Prieto-Arroyo I, Urbánek P, Steinbrenner H, Monsalve M. Redox regulation of FoxO transcription factors. Redox Biol. 2015 doi: 10.1016/j.redox.2015.06.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2015.06.019</ArticleId>
            <ArticleId IdType="pmc">PMC4511623</ArticleId>
            <ArticleId IdType="pubmed">26184557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15–6. 10.1038/358015a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1614522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21(10):607–632. doi: 10.1038/s41580-020-0255-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41580-020-0255-7</ArticleId>
            <ArticleId IdType="pubmed">32576977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei P, Ayton S, Bush AI, Adlard PA. GSK-3 in neurodegenerative diseases. Int J Alzheimer’s Dis. 2011;2011:1–9. doi: 10.4061/2011/189246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4061/2011/189246</ArticleId>
            <ArticleId IdType="pmc">PMC3100544</ArticleId>
            <ArticleId IdType="pubmed">21629738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Li X, Ning G, Zhu S, Ma X, Liu X, et al.  The Machado-Joseph Disease Deubiquitinase Ataxin-3 regulates the stability and apoptotic function of p53. PLoS Biol. 2016;14(11):e2000733. doi: 10.1371/journal.pbio.2000733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pbio.2000733</ArticleId>
            <ArticleId IdType="pmc">PMC5112960</ArticleId>
            <ArticleId IdType="pubmed">27851749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcelo A, Brito F, Carmo-Silva S, Matos CA, Alves-Cruzeiro J, Vasconcelos-Ferreira A, Koppenol R, Mendonça L, de Almeida LP, Nóbrega C. Cordycepin activates autophagy through AMPK phosphorylation to reduce abnormalities in Machado-Joseph disease models. Hum Mol Genet. 2019;28(1):51–63. doi: 10.1093/hmg/ddy328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddy328</ArticleId>
            <ArticleId IdType="pubmed">30219871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maqbool M, Hoda N. GSK3 inhibitors in the therapeutic development of diabetes, cancer and Neurodegeneration: past, present and future. Curr Pharm Des. 2017;23(29):4332–4350. doi: 10.2174/1381612823666170714141450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1381612823666170714141450</ArticleId>
            <ArticleId IdType="pubmed">28714403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320–328. doi: 10.1016/j.tibs.2011.03.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2011.03.006</ArticleId>
            <ArticleId IdType="pmc">PMC3112285</ArticleId>
            <ArticleId IdType="pubmed">21531565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menzies FM, Huebener J, Renna M, Bonin M, Riess O, Rubinsztein DC. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain. 2010;133(Pt 1):93–104. doi: 10.1093/brain/awp292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awp292</ArticleId>
            <ArticleId IdType="pmc">PMC2801325</ArticleId>
            <ArticleId IdType="pubmed">20007218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyuhas O. Ribosomal protein S6 phosphorylation. Int Rev Cell Mol Biol. 2015;320:41–73. 10.1016/bs.ircmb.2015.07.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26614871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mueller T, Breuer P, Schmitt I, Walter J, Evert BO, Wüllner U. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Hum Mol Genet. 2009;18:3334–3343. doi: 10.1093/hmg/ddp274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddp274</ArticleId>
            <ArticleId IdType="pubmed">19542537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popova TG, Espina V, Zhou W, Mueller C, Liotta L, Popov SG. Whole proteome analysis of mouse lymph nodes in cutaneous anthrax. PLoS ONE. 2014;9(10):e110873. doi: 10.1371/journal.pone.0110873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0110873</ArticleId>
            <ArticleId IdType="pmc">PMC4203832</ArticleId>
            <ArticleId IdType="pubmed">25329596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popova TG, Espina V, Liotta LA, Popov SG. Reverse-phase microarray analysis reveals novel targets in lymph nodes of bacillus anthracis spore-challenged mice. PLoS ONE. 2015;10(6):e0129860. doi: 10.1371/journal.pone.0129860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0129860</ArticleId>
            <ArticleId IdType="pmc">PMC4474663</ArticleId>
            <ArticleId IdType="pubmed">26091359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proctor CJ, Gray DA. GSK3 and p53 - is there a link in Alzheimer’s disease? Mol Neurodegen. 2010;5(7):1–15. doi: 10.1186/1750-1326-5-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1750-1326-5-7</ArticleId>
            <ArticleId IdType="pmc">PMC2831894</ArticleId>
            <ArticleId IdType="pubmed">20181016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramdzan YM, Trubetskov MM, Ormsby AR, Newcombe EA, Sui X, Tobin MJ, et al.  huntingtin inclusions trigger cellular quiescence, deactivate apoptosis, and lead to delayed necrosis. Cell Reports. 2017;19(5):919–927. doi: 10.1016/j.celrep.2017.04.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.04.029</ArticleId>
            <ArticleId IdType="pubmed">28467905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sacco JJ, Yau TY, Darling S, Patel V, Liu H, Urbé S, et al. The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells. Oncogene. 2013. 10.1038/onc.2013.512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4351423</ArticleId>
            <ArticleId IdType="pubmed">24292675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salter MW, Kalia LV. Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci. 2004;5(4):317–328. doi: 10.1038/nrn1368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn1368</ArticleId>
            <ArticleId IdType="pubmed">15034556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt J, Mayer AK, Bakula D, Freude J, Weber JJ, Weiss A, et al.  Vulnerability of frontal brain neurons for the toxicity of expanded ataxin-3. Hum Mol Genet. 2019;28(9):1463–1473. doi: 10.1093/hmg/ddy437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddy437</ArticleId>
            <ArticleId IdType="pubmed">30576445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmitt I, Linden M, Khazneh H, Evert BO, Breuer P, Klockgether T, et al.  Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem Biophys Res Commun. 2007;362:734–739. doi: 10.1016/j.bbrc.2007.08.062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2007.08.062</ArticleId>
            <ArticleId IdType="pubmed">17764659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi C-SS, Shenderov K, Huang N-NN, Kabat J, Abu-Asab M, Fitzgerald KA, et al.  Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol. 2012;13(3):255–263. doi: 10.1038/ni.2215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2215</ArticleId>
            <ArticleId IdType="pmc">PMC4116819</ArticleId>
            <ArticleId IdType="pubmed">22286270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silva-Fernandes A, Duarte-Silva S, Neves-Carvalho A, Amorim M, Soares-Cunha C, Oliveira P, Thirstrup K, Teixeira-Castro A, Maciel P. Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease. Neurotherapeutics. 2014;11(2):433–449. doi: 10.1007/s13311-013-0255-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-013-0255-9</ArticleId>
            <ArticleId IdType="pmc">PMC3996110</ArticleId>
            <ArticleId IdType="pubmed">24477711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sowa AS, Martin E, Martins IM, Schmidt J, Depping R, Weber JJ, et al.  Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3. Proc Natl Acad Sci. 2018;115(11):E2624–E2633. doi: 10.1073/pnas.1716071115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1716071115</ArticleId>
            <ArticleId IdType="pmc">PMC5856529</ArticleId>
            <ArticleId IdType="pubmed">29476013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spooren A, Kolmus K, Laureys G, Clinckers R, De Keyser J, Haegeman G, et al.  Interleukin-6, a mental cytokine. Brain Res Rev. 2011 doi: 10.1016/j.brainresrev.2011.01.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainresrev.2011.01.002</ArticleId>
            <ArticleId IdType="pubmed">21238488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Troussard AA, Tan C, Yoganathan TN, Dedhar S. Cell-extracellular matrix interactions stimulate the AP-1 transcription factor in an integrin-linked kinase- and glycogen synthase kinase 3-dependent manner. Mol Cell Biol. 1999;19:7420–7427. doi: 10.1128/MCB.19.11.7420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.19.11.7420</ArticleId>
            <ArticleId IdType="pmc">PMC84735</ArticleId>
            <ArticleId IdType="pubmed">10523630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turenne GA, Price BD. Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53’s transcriptional activity. BMC Cell Biol. 2001;2:12. doi: 10.1186/1471-2121-2-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2121-2-12</ArticleId>
            <ArticleId IdType="pmc">PMC35361</ArticleId>
            <ArticleId IdType="pubmed">11483158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vinayagam A, Stelzl U, Foulle R, Plassmann S, Zenkner M, Timm J, et al.  A directed protein interaction network for investigating intracellular signal transduction. Sci Signal. 2011;4(189):rs8. doi: 10.1126/scisignal.2001699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2001699</ArticleId>
            <ArticleId IdType="pubmed">21900206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Reiser G. The role of the Ca 2+-sensitive tyrosine kinase Pyk2 and Src in thrombin signalling in rat astrocytes. J Neurochem. 2003;84(6):1349–1357. doi: 10.1046/j.1471-4159.2003.01637.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1471-4159.2003.01637.x</ArticleId>
            <ArticleId IdType="pubmed">12614335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warden SM, Richardson C, O'Donnell J, Jr, Stapleton D, Kemp BE, Witters LA. Post-translational modifications of the beta-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. Biochem J. 2001;354(Pt 2):275–283. doi: 10.1042/0264-6021:3540275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/0264-6021:3540275</ArticleId>
            <ArticleId IdType="pmc">PMC1221653</ArticleId>
            <ArticleId IdType="pubmed">11171104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JJ, Sowa AS, Binder T, Hübener J. From pathways to targets: understanding the mechanisms behind polyglutamine disease. Biomed Res Int. 2014 doi: 10.1155/2014/701758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/701758</ArticleId>
            <ArticleId IdType="pmc">PMC4189765</ArticleId>
            <ArticleId IdType="pubmed">25309920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber JJ, Haas E, Maringer Y, Hauser S, Casadei NLP, Chishti AH, Riess O, Hübener-Schmid J. Calpain-1 ablation partially rescues disease-associated hallmarks in models of Machado-Joseph disease. Hum Mol Genet. 2020;29(6):892–906. doi: 10.1093/hmg/ddaa010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddaa010</ArticleId>
            <ArticleId IdType="pmc">PMC7158375</ArticleId>
            <ArticleId IdType="pubmed">31960910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wellington CL, Hayden MR. Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clin Genet. 2000;57(1):1–10. doi: 10.1034/j.1399-0004.2000.570101.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1034/j.1399-0004.2000.570101.x</ArticleId>
            <ArticleId IdType="pubmed">10733228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welsh GI, Proud CG. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J. 1993;294(Pt 3):625–629. doi: 10.1042/bj2940625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/bj2940625</ArticleId>
            <ArticleId IdType="pmc">PMC1134506</ArticleId>
            <ArticleId IdType="pubmed">8397507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiatr K, Piasecki P, Marczak Ł, Wojciechowski P, Kurkowiak M, Płoski R, Rydzanicz M, Handschuh L, Jungverdorben J, Brüstle O, Figlerowicz M, Figiel M. Altered levels of proteins and phosphoproteins, in the absence of early causative transcriptional changes, shape the molecular pathogenesis in the brain of young presymptomatic Ki91 SCA3/MJD Mouse. Mol Neurobiol. 2019;56(12):8168–8202. doi: 10.1007/s12035-019-01643-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-019-01643-4</ArticleId>
            <ArticleId IdType="pmc">PMC6834541</ArticleId>
            <ArticleId IdType="pubmed">31201651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson B, Liotta LA, Petricoin E., 3rd Monitoring proteins and protein networks using reverse phase protein arrays. Dis Markers. 2010;28(4):225–232. doi: 10.3233/DMA-2010-0705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/DMA-2010-0705</ArticleId>
            <ArticleId IdType="pmc">PMC3833243</ArticleId>
            <ArticleId IdType="pubmed">20534907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Z, Shi C, Zhou L, Li Y, Yang J, Liu Y, et al.  Metabolic profiling reveals biochemical pathways and potential biomarkers of spinocerebellar ataxia 3. Front Mol Neurosci. 2019;12:159. doi: 10.3389/fnmol.2019.00159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2019.00159</ArticleId>
            <ArticleId IdType="pmc">PMC6611058</ArticleId>
            <ArticleId IdType="pubmed">31316347</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
